Edaravone for acute ischaemic stroke
Background Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke. Objectives To assess the effica...
Gespeichert in:
| Veröffentlicht in: | Cochrane database of systematic reviews 2011-12, Vol.2011 (12), p.CD007230-CD007230 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | CD007230 |
|---|---|
| container_issue | 12 |
| container_start_page | CD007230 |
| container_title | Cochrane database of systematic reviews |
| container_volume | 2011 |
| creator | Feng, Shejun Yang, Qingwei Liu, Ming Li, Weizheng Yuan, Wenming Zhang, Shihong Wu, Bo Li, Juntao Liu, Ming |
| description | Background
Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.
Objectives
To assess the efficacy and safety of edaravone for acute ischaemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (November 2010) and the Chinese Stroke Trials Register (November 2010). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 4), MEDLINE (1950 to November 2010), EMBASE (1980 to November 2010), China National Knowledge Infrastructure (1979 to November 2010), Chinese Biomedical Database (1979 to November 2010), Chinese Evidence‐Based Medicine Database (November 2010) and Chinese Science and Technology Journals Database (1980 to November 2010). In an attempt to identify further published, unpublished and ongoing trials we searched reference lists and clinical trials and research registers, and contacted a pharmaceutical company, researchers and study authors.
Selection criteria
We included randomised controlled trials comparing edaravone with placebo or no intervention in patients with acute ischaemic stroke.
Data collection and analysis
Two review authors selected trials for inclusion, assessed trial quality and independently extracted the data.
Main results
We included three trials, involving 496 participants, and defined four trials as waiting assessment. All three included trials were of edaravone plus another treatment compared with the other treatment alone. The dose of edaravone injections in the three trials was the same at 60 mg per day. The course of treatment in all three trials is 14 days. None of the included trials reported the pre‐specified primary outcome of death or dependency defined using the modified Rankin scale during the follow‐up period. The three trials evaluated the effect of edaravone at different times and using different methods. All three trials reported adverse events; there were no differences between the treatment group and the control group. Overall, edaravone appeared to increase the proportion of participants with marked neurological improvement compared with the control group, and the difference was significant (risk ratio (RR) 1.99, 95% confidence interval (CI) 1.60 to 2.49).
Authors' conclusions
The risk of bias in the included trials was |
| doi_str_mv | 10.1002/14651858.CD007230.pub2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_911928916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>911928916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3692-1313876decb7af9c85d2fc03cfe5028c43d4aea153f700e96fb4ac9abc0b61f23</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK3-hZKD4Cl1ZjfZJEeN9QMKXvS8bDazNJo0dbdR-u9NaCvixdMMzPsxPIxNEWYIwK8xkjGmcTrL7wASLmC27gp-xMbDIRwux7_2ETvz_g1AyIwnp2zEOUqMEMbscl5qpz_bFQW2dYE23YaCypulpqYygd-49p3O2YnVtaeL_Zyw1_v5S_4YLp4fnvKbRWiG4BAFijSRJZki0TYzaVxya0AYSzHw1ESijDRpjIVNACiTtoi0yXRhoJBouZiwq13u2rUfHfmNavpXqK71itrOqwwx42mGslfKndK41ntHVq1d1Wi3VQhqAKQOgNQBkBoA9cbpvqIrGip_bAciveB2J_iqatoq05ql6-v_yf3T8g0EIXS7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>911928916</pqid></control><display><type>article</type><title>Edaravone for acute ischaemic stroke</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Feng, Shejun ; Yang, Qingwei ; Liu, Ming ; Li, Weizheng ; Yuan, Wenming ; Zhang, Shihong ; Wu, Bo ; Li, Juntao ; Liu, Ming</creator><creatorcontrib>Feng, Shejun ; Yang, Qingwei ; Liu, Ming ; Li, Weizheng ; Yuan, Wenming ; Zhang, Shihong ; Wu, Bo ; Li, Juntao ; Liu, Ming</creatorcontrib><description>Background
Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.
Objectives
To assess the efficacy and safety of edaravone for acute ischaemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (November 2010) and the Chinese Stroke Trials Register (November 2010). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 4), MEDLINE (1950 to November 2010), EMBASE (1980 to November 2010), China National Knowledge Infrastructure (1979 to November 2010), Chinese Biomedical Database (1979 to November 2010), Chinese Evidence‐Based Medicine Database (November 2010) and Chinese Science and Technology Journals Database (1980 to November 2010). In an attempt to identify further published, unpublished and ongoing trials we searched reference lists and clinical trials and research registers, and contacted a pharmaceutical company, researchers and study authors.
Selection criteria
We included randomised controlled trials comparing edaravone with placebo or no intervention in patients with acute ischaemic stroke.
Data collection and analysis
Two review authors selected trials for inclusion, assessed trial quality and independently extracted the data.
Main results
We included three trials, involving 496 participants, and defined four trials as waiting assessment. All three included trials were of edaravone plus another treatment compared with the other treatment alone. The dose of edaravone injections in the three trials was the same at 60 mg per day. The course of treatment in all three trials is 14 days. None of the included trials reported the pre‐specified primary outcome of death or dependency defined using the modified Rankin scale during the follow‐up period. The three trials evaluated the effect of edaravone at different times and using different methods. All three trials reported adverse events; there were no differences between the treatment group and the control group. Overall, edaravone appeared to increase the proportion of participants with marked neurological improvement compared with the control group, and the difference was significant (risk ratio (RR) 1.99, 95% confidence interval (CI) 1.60 to 2.49).
Authors' conclusions
The risk of bias in the included trials was moderate and the sample was small. Hence, although the data in this review show an effective treatment trend of edaravone for acute ischaemic stroke, further large, high‐quality trials are required to confirm this trend.</description><identifier>ISSN: 1465-1858</identifier><identifier>EISSN: 1465-1858</identifier><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD007230.pub2</identifier><identifier>PMID: 22161410</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Antipyrine ; Antipyrine - analogs & derivatives ; Antipyrine - therapeutic use ; Brain Ischemia ; Brain Ischemia - complications ; Edaravone ; Free Radical Scavengers ; Free Radical Scavengers - therapeutic use ; Heart & circulation ; Humans ; ISCHAEMIC/UNSPECIFIED STROKE, TRANSIENT ISCHAEMIC ATTACK ; Ischemic stroke/TIA: treatment ; Medical therapy ; Medicine General & Introductory Medical Sciences ; Neurology ; Neuroprotection ; Neuroprotective Agents ; Neuroprotective Agents - therapeutic use ; Randomized Controlled Trials as Topic ; Stroke ; Stroke - drug therapy ; Stroke - etiology ; Treatment</subject><ispartof>Cochrane database of systematic reviews, 2011-12, Vol.2011 (12), p.CD007230-CD007230</ispartof><rights>Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3692-1313876decb7af9c85d2fc03cfe5028c43d4aea153f700e96fb4ac9abc0b61f23</citedby><cites>FETCH-LOGICAL-c3692-1313876decb7af9c85d2fc03cfe5028c43d4aea153f700e96fb4ac9abc0b61f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22161410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feng, Shejun</creatorcontrib><creatorcontrib>Yang, Qingwei</creatorcontrib><creatorcontrib>Liu, Ming</creatorcontrib><creatorcontrib>Li, Weizheng</creatorcontrib><creatorcontrib>Yuan, Wenming</creatorcontrib><creatorcontrib>Zhang, Shihong</creatorcontrib><creatorcontrib>Wu, Bo</creatorcontrib><creatorcontrib>Li, Juntao</creatorcontrib><creatorcontrib>Liu, Ming</creatorcontrib><title>Edaravone for acute ischaemic stroke</title><title>Cochrane database of systematic reviews</title><addtitle>Cochrane Database Syst Rev</addtitle><description>Background
Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.
Objectives
To assess the efficacy and safety of edaravone for acute ischaemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (November 2010) and the Chinese Stroke Trials Register (November 2010). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 4), MEDLINE (1950 to November 2010), EMBASE (1980 to November 2010), China National Knowledge Infrastructure (1979 to November 2010), Chinese Biomedical Database (1979 to November 2010), Chinese Evidence‐Based Medicine Database (November 2010) and Chinese Science and Technology Journals Database (1980 to November 2010). In an attempt to identify further published, unpublished and ongoing trials we searched reference lists and clinical trials and research registers, and contacted a pharmaceutical company, researchers and study authors.
Selection criteria
We included randomised controlled trials comparing edaravone with placebo or no intervention in patients with acute ischaemic stroke.
Data collection and analysis
Two review authors selected trials for inclusion, assessed trial quality and independently extracted the data.
Main results
We included three trials, involving 496 participants, and defined four trials as waiting assessment. All three included trials were of edaravone plus another treatment compared with the other treatment alone. The dose of edaravone injections in the three trials was the same at 60 mg per day. The course of treatment in all three trials is 14 days. None of the included trials reported the pre‐specified primary outcome of death or dependency defined using the modified Rankin scale during the follow‐up period. The three trials evaluated the effect of edaravone at different times and using different methods. All three trials reported adverse events; there were no differences between the treatment group and the control group. Overall, edaravone appeared to increase the proportion of participants with marked neurological improvement compared with the control group, and the difference was significant (risk ratio (RR) 1.99, 95% confidence interval (CI) 1.60 to 2.49).
Authors' conclusions
The risk of bias in the included trials was moderate and the sample was small. Hence, although the data in this review show an effective treatment trend of edaravone for acute ischaemic stroke, further large, high‐quality trials are required to confirm this trend.</description><subject>Antipyrine</subject><subject>Antipyrine - analogs & derivatives</subject><subject>Antipyrine - therapeutic use</subject><subject>Brain Ischemia</subject><subject>Brain Ischemia - complications</subject><subject>Edaravone</subject><subject>Free Radical Scavengers</subject><subject>Free Radical Scavengers - therapeutic use</subject><subject>Heart & circulation</subject><subject>Humans</subject><subject>ISCHAEMIC/UNSPECIFIED STROKE, TRANSIENT ISCHAEMIC ATTACK</subject><subject>Ischemic stroke/TIA: treatment</subject><subject>Medical therapy</subject><subject>Medicine General & Introductory Medical Sciences</subject><subject>Neurology</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Stroke</subject><subject>Stroke - drug therapy</subject><subject>Stroke - etiology</subject><subject>Treatment</subject><issn>1465-1858</issn><issn>1465-1858</issn><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>RWY</sourceid><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRbK3-hZKD4Cl1ZjfZJEeN9QMKXvS8bDazNJo0dbdR-u9NaCvixdMMzPsxPIxNEWYIwK8xkjGmcTrL7wASLmC27gp-xMbDIRwux7_2ETvz_g1AyIwnp2zEOUqMEMbscl5qpz_bFQW2dYE23YaCypulpqYygd-49p3O2YnVtaeL_Zyw1_v5S_4YLp4fnvKbRWiG4BAFijSRJZki0TYzaVxya0AYSzHw1ESijDRpjIVNACiTtoi0yXRhoJBouZiwq13u2rUfHfmNavpXqK71itrOqwwx42mGslfKndK41ntHVq1d1Wi3VQhqAKQOgNQBkBoA9cbpvqIrGip_bAciveB2J_iqatoq05ql6-v_yf3T8g0EIXS7</recordid><startdate>20111207</startdate><enddate>20111207</enddate><creator>Feng, Shejun</creator><creator>Yang, Qingwei</creator><creator>Liu, Ming</creator><creator>Li, Weizheng</creator><creator>Yuan, Wenming</creator><creator>Zhang, Shihong</creator><creator>Wu, Bo</creator><creator>Li, Juntao</creator><creator>Liu, Ming</creator><general>John Wiley & Sons, Ltd</general><scope>7PX</scope><scope>RWY</scope><scope>ZYTZH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111207</creationdate><title>Edaravone for acute ischaemic stroke</title><author>Feng, Shejun ; Yang, Qingwei ; Liu, Ming ; Li, Weizheng ; Yuan, Wenming ; Zhang, Shihong ; Wu, Bo ; Li, Juntao ; Liu, Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3692-1313876decb7af9c85d2fc03cfe5028c43d4aea153f700e96fb4ac9abc0b61f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antipyrine</topic><topic>Antipyrine - analogs & derivatives</topic><topic>Antipyrine - therapeutic use</topic><topic>Brain Ischemia</topic><topic>Brain Ischemia - complications</topic><topic>Edaravone</topic><topic>Free Radical Scavengers</topic><topic>Free Radical Scavengers - therapeutic use</topic><topic>Heart & circulation</topic><topic>Humans</topic><topic>ISCHAEMIC/UNSPECIFIED STROKE, TRANSIENT ISCHAEMIC ATTACK</topic><topic>Ischemic stroke/TIA: treatment</topic><topic>Medical therapy</topic><topic>Medicine General & Introductory Medical Sciences</topic><topic>Neurology</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Stroke</topic><topic>Stroke - drug therapy</topic><topic>Stroke - etiology</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feng, Shejun</creatorcontrib><creatorcontrib>Yang, Qingwei</creatorcontrib><creatorcontrib>Liu, Ming</creatorcontrib><creatorcontrib>Li, Weizheng</creatorcontrib><creatorcontrib>Yuan, Wenming</creatorcontrib><creatorcontrib>Zhang, Shihong</creatorcontrib><creatorcontrib>Wu, Bo</creatorcontrib><creatorcontrib>Li, Juntao</creatorcontrib><creatorcontrib>Liu, Ming</creatorcontrib><collection>Wiley-Blackwell Cochrane Library</collection><collection>Cochrane Library</collection><collection>Cochrane Library (Open Aceess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feng, Shejun</au><au>Yang, Qingwei</au><au>Liu, Ming</au><au>Li, Weizheng</au><au>Yuan, Wenming</au><au>Zhang, Shihong</au><au>Wu, Bo</au><au>Li, Juntao</au><au>Liu, Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Edaravone for acute ischaemic stroke</atitle><jtitle>Cochrane database of systematic reviews</jtitle><addtitle>Cochrane Database Syst Rev</addtitle><date>2011-12-07</date><risdate>2011</risdate><volume>2011</volume><issue>12</issue><spage>CD007230</spage><epage>CD007230</epage><pages>CD007230-CD007230</pages><issn>1465-1858</issn><eissn>1465-1858</eissn><eissn>1469-493X</eissn><abstract>Background
Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.
Objectives
To assess the efficacy and safety of edaravone for acute ischaemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (November 2010) and the Chinese Stroke Trials Register (November 2010). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 4), MEDLINE (1950 to November 2010), EMBASE (1980 to November 2010), China National Knowledge Infrastructure (1979 to November 2010), Chinese Biomedical Database (1979 to November 2010), Chinese Evidence‐Based Medicine Database (November 2010) and Chinese Science and Technology Journals Database (1980 to November 2010). In an attempt to identify further published, unpublished and ongoing trials we searched reference lists and clinical trials and research registers, and contacted a pharmaceutical company, researchers and study authors.
Selection criteria
We included randomised controlled trials comparing edaravone with placebo or no intervention in patients with acute ischaemic stroke.
Data collection and analysis
Two review authors selected trials for inclusion, assessed trial quality and independently extracted the data.
Main results
We included three trials, involving 496 participants, and defined four trials as waiting assessment. All three included trials were of edaravone plus another treatment compared with the other treatment alone. The dose of edaravone injections in the three trials was the same at 60 mg per day. The course of treatment in all three trials is 14 days. None of the included trials reported the pre‐specified primary outcome of death or dependency defined using the modified Rankin scale during the follow‐up period. The three trials evaluated the effect of edaravone at different times and using different methods. All three trials reported adverse events; there were no differences between the treatment group and the control group. Overall, edaravone appeared to increase the proportion of participants with marked neurological improvement compared with the control group, and the difference was significant (risk ratio (RR) 1.99, 95% confidence interval (CI) 1.60 to 2.49).
Authors' conclusions
The risk of bias in the included trials was moderate and the sample was small. Hence, although the data in this review show an effective treatment trend of edaravone for acute ischaemic stroke, further large, high‐quality trials are required to confirm this trend.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>22161410</pmid><doi>10.1002/14651858.CD007230.pub2</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-1858 |
| ispartof | Cochrane database of systematic reviews, 2011-12, Vol.2011 (12), p.CD007230-CD007230 |
| issn | 1465-1858 1465-1858 1469-493X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_911928916 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antipyrine Antipyrine - analogs & derivatives Antipyrine - therapeutic use Brain Ischemia Brain Ischemia - complications Edaravone Free Radical Scavengers Free Radical Scavengers - therapeutic use Heart & circulation Humans ISCHAEMIC/UNSPECIFIED STROKE, TRANSIENT ISCHAEMIC ATTACK Ischemic stroke/TIA: treatment Medical therapy Medicine General & Introductory Medical Sciences Neurology Neuroprotection Neuroprotective Agents Neuroprotective Agents - therapeutic use Randomized Controlled Trials as Topic Stroke Stroke - drug therapy Stroke - etiology Treatment |
| title | Edaravone for acute ischaemic stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T08%3A17%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Edaravone%20for%20acute%20ischaemic%20stroke&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Feng,%20Shejun&rft.date=2011-12-07&rft.volume=2011&rft.issue=12&rft.spage=CD007230&rft.epage=CD007230&rft.pages=CD007230-CD007230&rft.issn=1465-1858&rft.eissn=1465-1858&rft_id=info:doi/10.1002/14651858.CD007230.pub2&rft_dat=%3Cproquest_cross%3E911928916%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=911928916&rft_id=info:pmid/22161410&rfr_iscdi=true |